Literature DB >> 14969746

A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease.

Robert C Murphy1, Anne Messer.   

Abstract

Huntington's disease (HD) is a progressive, hereditary, neurodegenerative disorder caused by an expanded polyglutamine tract in huntingtin protein, leading to misfolding and abnormal protein-protein interactions. Reducing the initial misfolding should lead to decreased pathogenesis. We show that malonate stress increases the number of dead or dying cells when organotypic slice cultures are transduced to express pathological-length huntingtin fragments. Co-transfected anti-HD single-chain Fv (sFv) intrabodies can reverse this HD-specific increase in malonate-induced morbidity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14969746     DOI: 10.1016/j.molbrainres.2003.11.011

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  23 in total

Review 1.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

Review 2.  High throughput screening for neurodegeneration and complex disease phenotypes.

Authors:  Hemant Varma; Donald C Lo; Brent R Stockwell
Journal:  Comb Chem High Throughput Screen       Date:  2008-03       Impact factor: 1.339

3.  Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.

Authors:  Sharareh Emadi; Hedieh Barkhordarian; Min S Wang; Philip Schulz; Michael R Sierks
Journal:  J Mol Biol       Date:  2007-03-07       Impact factor: 5.469

4.  Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.

Authors:  David W Colby; Yijia Chu; John P Cassady; Martin Duennwald; Helen Zazulak; Jack M Webster; Anne Messer; Susan Lindquist; Vernon Martin Ingram; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-14       Impact factor: 11.205

Review 5.  Gene therapy in mouse models of huntington disease.

Authors:  Amber L Southwell; Paul H Patterson
Journal:  Neuroscientist       Date:  2011-04       Impact factor: 7.519

6.  Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

Authors:  William J Wolfgang; Todd W Miller; Jack M Webster; James S Huston; Leslie M Thompson; J Lawrence Marsh; Anne Messer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

7.  Detecting morphologically distinct oligomeric forms of alpha-synuclein.

Authors:  Sharareh Emadi; Srinath Kasturirangan; Min S Wang; Philip Schulz; Michael R Sierks
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

8.  Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Authors:  Erik Kvam; Brent L Nannenga; Min S Wang; Zongjian Jia; Michael R Sierks; Anne Messer
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

9.  Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.

Authors:  Amber L Southwell; Jan Ko; Paul H Patterson
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

10.  An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity.

Authors:  Sandra M Lynch; Chun Zhou; Anne Messer
Journal:  J Mol Biol       Date:  2007-12-05       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.